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Purpose: The serum levels of soluble triggering receptor expressed on myeloid 
cells-1 (sTREM-1) have recently been shown to be correlated highly with disease 
activity in patients with intestinal Behçet’s disease (BD). However, it remains un-
clear whether sTREM-1 levels reflect endoscopic activity in intestinal BD. This 
study aimed to evaluate the correlation of sTREM-1 levels with endoscopic activi-
ty in intestinal BD. Materials and Methods: A total of 84 patients with intestinal 
BD were enrolled. Endoscopic activity was compared with sTREM-1 levels as 
well as other laboratory findings, including erythrocyte sedimentation rate (ESR) 
and C-reactive protein (CRP). Results: sTREM-1 levels were significantly in-
creased in intestinal BD patients compared with controls (37.98±27.09 pg/mL vs. 
16.65±7.76 pg/mL, p=0.002), however, there was no difference between endo-
scopically quiescent and active diseases (43.53±24.95 pg/mL vs. 42.22±32.68 pg/
mL, p=0.819). Moreover, serum sTREM-1 levels did not differ in terms of num-
ber, shape, depth, size, margin, or type of ulcer in patients with intestinal BD. 
However, mean ESR and CRP levels in patients with active disease were signifi-
cantly higher than those in patients with quiescent disease (p=0.001, p<0.001, re-
spectively). In addition, endoscopic activity scores for intestinal BD were correlat-
ed significantly with both CRP levels (γ=0.329) and ESR (γ=0.298), but not with 
sTREM-1 levels (γ=0.166). Conclusion: Unlike CRP levels and ESR, serum 
sTREM-1 levels were not correlated with endoscopic activity in patients with in-
testinal BD.
Key Words:   C-reactive protein, endoscopic activity, erythrocyte sedimentation 
rate, intestinal Behçet’s disease, triggering receptor expressed on 
myeloid cells-1
INTRODUCTION
Intestinal Behçet’s disease (BD), generally considered as a type of inflammatory 
bowel disease (IBD), has an unpredictable disease course with exacerbations and 
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MATERIALS AND METHODS
　　　
Patients 
Between July 2006 and December 2009, 84 patients with 
intestinal BD seen at Severance Hospital, Yonsei Universi-
ty, Seoul, Korea were enrolled in our study. Intestinal BD 
was diagnosed according to the previously established cri-
teria, based on colonoscopic features and clinical manifes-
tations, using a modified Delphi process.20 Patients classi-
fied as definite, probable, and suspected were included in 
this study. The exclusion criteria were as follows: 1) coex-
isting infectious or ischemic colitis, 2) other coexisting lo-
calized or systemic infections, 3) a diagnosis of liver cirrho-
sis, 4) a history of administration of anti-tumor necrosis 
factor-α (TNF-α) antibodies, and 5) a history of bowel re-
section. The control group included six healthy individuals 
who had no gastrointestinal symptoms, took no regular 
medications, and had a normal complete blood count and a 
normal biochemical profile, including ESR and CRP levels. 
All control subjects underwent colonoscopy for routine 
check-up, which revealed grossly normal findings. 
Samples
At the time of colonoscopy, sTREM-1 levels as well as other 
laboratory findings including ESR and CRP were measured 
and compared with endoscopic activity. Serum sTREM-1 
levels were measured using a commercialized, specific, en-
zyme-linked immunosorbent assay kit (R&D systems, Min-
neapolis, MN, USA) according to the manufacturer’s proto-
col. Briefly, samples were incubated in wells coated with a 
TREM-1-specific monoclonal antibody for 2 h at room 
temperature (RT). After washing the wells four times, a 
peroxidase-conjugated anti-TREM-1 polyclonal antibody 
was added to the wells, and the samples were incubated for 
2 h at RT. After washing an additional four times, the sub-
strate solution was added, and after a 30-min incubation at 
RT, the stop solution was added to terminate the enzyme re-
action. Absorbance was measured at 450 nm using a micro-
plate reader, with the wavelength corrected by measuring 
and comparing the absorbance to 540 nm. Measurements 
were performed in triplicate. ESR was determined from 
whole blood according to the Westergren method (Alifax, 
Padova, Italy). Serum CRP concentrations were assessed 
using a nephelometric method (Beckman Coulter, Fuller-
ton, CA, USA). This study was approved by the Institutional 
Review Board of Severance Hospital and all subjects pro-
remission.1 Therefore, the timely objective assessment of 
disease activity is indispensable in patients with intestinal 
BD to administer appropriate therapies and monitor the ef-
fect of treatment. In IBD, along with the clinical parameters, 
endoscopy is traditionally used to measure disease activity 
by directly evaluating the severity and extent of mucosal le-
sions.2,3 As mucosal healing has emerged as a key treatment 
goal in IBD,4,5 the role of endoscopy in monitoring disease 
activity has been highlighted. However, because endoscopy 
is an invasive and expensive procedure, non-invasive, surro-
gate biomarkers are also actively being explored to predict 
the degree of inflammation and monitor disease activity.6,7 
Among such biomarkers, erythrocyte sedimentation rate 
(ESR) and serum concentrations of C-reactive protein (CRP) 
have been the most studied, but these biomarkers have shown 
only a modest performance yet.
Although intestinal BD shares many clinical features 
with IBD and treatment is largely based on the strategies of 
IBD, recurrence and surgical intervention rates are reported 
to be even higher in patients with intestinal BD than with 
Crohn’s disease (CD).8 In this regard, therefore, there is a 
critical need to develop accurate tools to measure disease 
activity for intestinal BD. However, data regarding the ob-
jective means of determining disease activity of intestinal 
BD are extremely limited. We have recently reported the 
disease activity index for intestinal BD that assesses clinical 
activity9 and an endoscopic severity model, respectively,10 
but no biomarkers were identified to be associated with in-
testinal BD.
Triggering receptor expressed on myeloid cells-1 (TREM-
1) is a member of the immunoglobulin superfamily and is 
constitutively expressed on the surfaces of neutrophils and 
monocyte/macrophages; it triggers the synthesis and secretion 
of proinflammatory cytokines.11 Levels of soluble TREM-1 
(sTREM-1) were found to be elevated, not only in acute in-
flammatory conditions such as pneumonia and sepsis,12,13 
but also in chronic inflammatory disorders such as rheuma-
toid arthritis.14 Moreover, recent studies found that TREM-
1 was upregulated in the inflamed mucosa of patients with 
IBD15 and sTREM-1 correlated with both clinical and en-
doscopic disease activities of ulcerative colitis (UC),16-18 im-
plicating the potential role of sTREM-1 to assess disease 
activity in IBD patients. Because we earlier showed that 
sTREM-1 correlated better with clinical disease activity than 
either ESR or CRP,19 in the present study, we aimed to eval-
uate whether sTREM-1 also could predict endoscopic ac-
tivity in intestinal BD compared to ESR or CRP.
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All statistical analyses were performed using SPSS soft-
ware (ver. 18.0; SPSS Inc., Chicago, IL, USA).
 
RESULTS
 
Baseline characteristics and serum sTREM-1 levels in 
patients with intestinal BD
Table 1 shows the clinical characteristics and laboratory 
findings of the 84 intestinal BD patients and 6 control sub-
jects enrolled in the study. There were no statistically signif-
icant differences between the two groups with respect to 
demographic properties such as gender or age. Of the 84 
patients with intestinal BD, 17 (20.2%) showed quiescent 
disease activity, 27 (32.1%) had mild activity, 26 (31.0%) 
had moderate activity, and 14 (16.7%) showed severe dis-
ease activity. 
Concentrations (mean±SD) of sTREM-1 in patients with 
intestinal BD (37.98±27.09 pg/mL) were significantly high-
er than those of healthy controls (16.65±7.76 pg/mL) (p= 
0.002), consistent with our previous data (Fig. 1).19 
Correlation of endoscopic activity with serum sTREM-1, 
CRP, and ESR in intestinal BD
The number of patients with endoscopically active disease 
was 61 (72.6%) and that with quiescent disease was 23 
(27.4%). The mean CRP and ESR levels in patients with ac-
tive disease were significantly higher than those in patients 
vided written informed consent. 
Correlations between 3 biomarkers and endoscopic 
activity
Endoscopic disease activity was divided into two categories 
as quiescent and active disease according to the ulcer status 
to investigate the relationship between endoscopic activity 
and biomarkers. In patients with active ulcers, variable en-
doscopic factors, including location, number, depth, shape, 
and size of ulcer, were measured to assess their correlations 
with sTREM-1. In addition, endoscopic activity was ad-
junctively determined in patients with intestinal BD using a 
recently developed, novel endoscopic severity model.10
Statistical analysis
Variables are expressed as means±standard deviation (SD). 
Continuous variables were compared using an independent t 
test or a Mann-Whitney U test, and categorical variables were 
compared with a chi-square test or Fisher’s exact test. Associ-
ations between endoscopic disease activity and sTREM-1, 
CRP, or ESR were assessed using Spearman’s rank correla-
tion coefficients (γ) for nonparametric correlations. The mul-
tivariate logistic analysis was performed to determine bio-
markers associated with endoscopically active disease. Serial 
receiver operating characteristic (ROC) curves [±95% confi-
dence interval (CI)] were used to define the diagnostic accu-
racy of sTREM-1, ESR, and CRP to predict endoscopically 
active disease. p<0.05 was considered statistically significant. 
Table 1. Baseline Characteristics of Healthy Subjects and Patients with Intestinal BD
Control (n=6) Intestinal BD (n=84)
Male (%) 3 (50.0) 39 (46.4)
Age (yrs, mean±SD) 36.83±5.31 43.83±13.10
Disease duration (months) NA 94.90±66.66
Endoscopic activity NA 67.61±19.16
    Remission NA    23 (27.4%)
    Active NA    61 (72.6%)
Clinical activity NA 47.32±36.93
    Quiescent NA    17 (20.2%)
    Mild NA    27 (32.1%)
    Moderate NA    26 (31.0%)
    Severe NA    14 (16.7%)
sTREM-1 (pg/mL, mean±SD) 16.65±7.76   37.98±27.09*
CRP (mg/dL, mean±SD) NA 1.25±2.02
ESR (mm/h, mean±SD) NA 31.94±23.46
BD, Behçet’s disease; NA, not applicable; sTREM-1, soluble triggering receptor expressed on myeloid cells-1; CRP, C-reactive protein; ESR, erythrocyte 
sedimentation rate.
*p<0.05 compared with controls.
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flares and poor overall prognosis in intestinal BD,8 assess-
ment of disease activity is inevitable to decide an appropri-
ate treatment plan and evaluate response. Although there are 
few studies to show high CRP level as a poor prognostic 
factor22 and association of anti-Saccharomyces cerevisiae 
antibody positivity with increased surgical rate,23 data on 
which biomarkers could predict disease activity of intesti-
nal BD are extremely limited.
Recently, as increased levels of sTREM-1 were observed 
in patients with moderate or severe IBD,15,16 sTREM-1 was 
evaluated as a promising biomarker to monitor disease activ-
ity in IBD. sTREM-1 levels were correlated most accurately 
with clinical and endoscopic disease activities in UC re-
gardless of disease extent.17,18 Jung, et al.19 also showed the 
with quiescent disease (1.60±2.28 mg/dL vs. 0.31±0.23 mg/
dL, p<0.001 and 36.18±24.62 mm/h vs. 20.70±15.54 mm/
h, p=0.001, respectively), whereas the mean sTREM-1 lev-
els in patients with active disease did not differ from those 
in patients with quiescent disease (43.53±24.95 pg/mL vs. 
42.22±32.68 pg/mL, p=0.819) (Table 2). Endoscopic activity 
score for intestinal BD correlated significantly with both 
CRP levels (γ=0.329, p=0.002) and ESR (γ=0.298, p=0.006), 
but not with sTREM-1 levels (γ=0.166, p=0.132). Among 
these, CRP levels showed the highest correlation (Supple-
mentary Fig. 1, only online). The results of multiple linear 
regression analyses for the three biomarkers associated 
with endoscopically active disease are shown in Table 3. 
Only CRP level was independently correlated with endo-
scopic activity after adjusting for other biomarkers (OR 
7.08, CI 1.24--40.33, p=0.027). 
Using ROC curves, CRP had the best discriminatory 
power [area under receiver operating characteristic (AU-
ROC) 0.737, p=0.001] in detecting endoscopically active 
disease, followed by ESR (AUROC 0.695, p=0.006) and 
sTREM-1 (AUROC 0.553, p=0.455) (Supplementary Ta-
ble 1, only online).
Differential expression of serum sTREM-1 levels 
according to endoscopic factors
To determine whether serum sTREM-1 levels differ accord-
ing to endoscopic factors, we analyzed 61 patients with en-
doscopically active disease. Serum sTREM-1 levels did not 
differ in terms of number, shape, depth, size, margin, or type 
of ulcer. However, serum sTREM-1 levels in patients with 
ileocecal area ulcer were significantly lower than those in 
patients with colonic ulcers (40.13±23.95 vs. 55.90±25.26, 
p=0.021) (Table 4).
DISCUSSION
Biomarkers have been investigated in IBD for assessment of 
disease activity, prediction of disease course and outcome, 
and monitoring effects of therapy. In addition to ESR and 
CRP, fecal markers have also been studied recently in IBD 
because they would be more specific in the absence of en-
teric infection.6,7 However, no single marker has so far been 
proven to be ideal, since ESR takes several days to decline 
due to long half lives even when rapid clinical improvement 
occurs,7 and CRP correlates less well with disease activity in 
UC compared to CD.21 Considering unpredictable disease 
Fig. 1. Serum sTREM-1 levels were significantly higher in patients with in-
testinal BD than in controls. BD, Behçet’s disease; sTREM-1, soluble trig-
gering receptor expressed on myeloid cells-1.
Table 2. Comparison of Serum sTREM-1, CRP, and ESR Lev-
els among the Patients with Endoscopically Inactive or Ac-
tive Disease
Active 
(n=61)
Quiescent 
(n=23)
p value
sTREM-1 43.53±24.95 42.22±32.68   0.819
CRP 1.60±2.28 0.31±0.23 <0.001
ESR 36.18±24.62 20.70±15.54   0.001
sTREM-1, soluble triggering receptor expressed on myeloid cells-1; CRP, 
C-reactive protein; ESR, erythrocyte sedimentation rate.
Table 3. Multivariate Analysis of Biological Markers Associ-
ated with Endoscopically Active Disease
Variables OR 95% CI p value
sTREM-1 0.99 0.97--1.01 0.502
CRP 7.08   1.24--40.33 0.027
ESR 1.01 0.97--1.04 0.752
OR, odds ratio; CI, confidence interval; sTREM-1, soluble triggering recep-
tor expressed on myeloid cells-1; CRP, C-reactive protein; ESR, erythrocyte 
sedimentation rate.
0
50
100
150
200
sT
RE
M
-1
 (p
g/
m
L)
Control Intestinal BD
p=0.002
Hyun Jung Lee, et al.
Yonsei Med J   http://www.eymj.org   Volume 55   Number 4   July 2014964
were no statistical differences in the intestinal complica-
tions and extraintestinal manifestations between the two 
groups in our study (data not shown), it is possible that 
sTREM-1 might be more specific and sensitive for intesti-
nal mucosa than either CRP or ESR in reflecting subclinical 
inflammation of intestinal BD. Such findings imply that 
sTREM-1 could play a role in discriminating intestinal BD 
from other functional disorders like irritable bowel syn-
drome (IBS), which often share clinical similarities and 
cause difficulties in diagnosis.28,29 Further studies are need-
ed to identify the potential value of sTREM-1 as a differen-
tial diagnostic marker.
In patients with intestinal BD, we did not find any corre-
lation between sTREM-1 levels and endoscopic activity, 
which was contradictory to our previous study that showed 
the highest correlation between sTREM-1 and clinical ac-
tivity.19 The reasons for this discrepancy are not clear, nev-
ertheless, it might be attributable to the different release 
pattern of TREM-1. Previously, S100A9 protein, which ex-
pression levels were significantly correlated with TREM-1 
levels,24 was found to be lower in ileal CD than colonic in-
flammation because of degradation during the passage from 
the ileum, which should be further tested.30 Since most pa-
tients with intestinal BD have lesions in the ileocecal re-
gion,8 sTREM-1 levels might not accurately reflect disease 
activity in intestinal BD. These hypotheses were verified in 
this study in that higher sTREM-1 levels were observed in 
other colonic areas than ileocecal areas in patients with en-
most close correlation between sTREM-1 and clinical ac-
tivity among serum biomarkers, including CRP and ESR in 
intestinal BD. Because there are no decisive conclusions 
about the role of sTREM-1 in IBD, we aimed to identify 
whether sTREM-1 was elevated in intestinal BD with en-
doscopically active disease and whether sTREM-1 could be 
a reliable marker to assess disease activity in patients with 
intestinal BD.
In the present study, we demonstrated that sTREM-1 lev-
els were significantly upregulated in intestinal BD patients 
compared to normal controls, the finding similar to data 
previously reported in IBD.15,17,24 Our findings thus suggest 
that sTREM-1 might be involved in the pathogenesis of in-
testinal BD, leading to increased proinflammatory media-
tors and contributing to sustained inflammation and disease 
exacerbation. However, among patients with intestinal BD, 
sTREM-1 was also elevated in endoscopically quiescent 
disease to similar levels as in active disease. Similarly, two 
interesting articles reveal the disparities in the relationship 
of sTREM-1 level with disease activity in IBD.24,25 One of 
the possible explanations is that, even in patients with qui-
escent disease, subclinical inflammation may be enough to 
cause bacterial translocation that may initiate the release of 
sTREM-1. It is also possible that since up to 50% of pa-
tients with intestinal BD have frequent intestinal complica-
tions, such as bowel perforation, fistula, and abscess forma-
tion,26,27 extraintestinal manifestations can affect sTREM-1 
levels irrespective of endoscopic activity. Because there 
Table 4. Serum sTREM-1 Levels According to the Endoscopic Factors in Patients with Endoscopically Active Disease
Endoscopic factors No. of patients (%) sTREM-1 (pg/mL) p value
Location 0.021
    Ileocecal area 47 (77.0) 40.13±23.95
    Other 14 (23.0) 55.90±25.26
Number 0.759
    Solitary 41 (67.2) 43.73±27.37
    ≥2 20 (32.8) 43.80±19.73
Shape 0.511
    Oval 31 (50.8) 43.17±23.38
    Geographic 16 (26.2) 38.48±21.34
    Volcano 14 (23.0) 51.06±31.54
Depth 0.222
    Aphthous 5 (8.2) 39.42±18.57
    Shallow 20 (32.8) 37.56±23.91
    Deep 36 (59.0) 47.80±26.00
Size 0.603
    <20 mm 29 (47.5) 41.78±22.61
    ≥20 mm 32 (52.5) 45.54±27.14
sTREM-1, soluble triggering receptor expressed on myeloid cells-1.
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